JP Morgan Chase’s Travere Therapeutics TVTX Stock Holding History

JP Morgan Chase’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-481,500	Closed	-$18.4M	–	7906
2025 Q4	$18.4M	Buy	481,500 +36,700	+8%	+$1.19M	﹤0.01%	2136
2025 Q3	$10.6M	Buy	444,800 +433,200	+3,734%	+$8.14M	﹤0.01%	2665
2025 Q2	$172K	Buy	11,600 +1,600	+16%	+$26.5K	﹤0.01%	5314
2025 Q1	$179K	Hold	10,000	–	–	﹤0.01%	5286
2024 Q4	$174K	Buy	+10,000	New	+$177K	﹤0.01%	5539
2023 Q4	–	Sell	-1,400	Closed	-$12.5K	–	7878
2023 Q3	$12.5K	Buy	+1,400	New	+$19.8K	﹤0.01%	6198
2019 Q4	–	Sell	-35,000	Closed	-$406K	–	5894
2019 Q3	$406K	Buy	+35,000	New	+$578K	﹤0.01%	4269
2016 Q3	–	Sell	-15,000	Closed	-$267K	–	4812
2016 Q2	$267K	Buy	+15,000	New	+$243K	﹤0.01%	3632

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase's TVTX Position: Q1 2026 in Review

JP Morgan Chase reduced its Travere Therapeutics (TVTX) stake by 10% in Q1 2026, selling an estimated $988K and leaving 288,551 shares worth $7.98M. The position accounts for ﹤0.01% of the portfolio, ranked #2885.

JP Morgan Chase first reported a position in TVTX in Q4 2015 and has held it in 41 quarters since. The position peaked at $35.2M in Q4 2021. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

JP Morgan Chase held 288,551 shares of Travere Therapeutics worth $7.98M as of Q1 2026.
JP Morgan Chase sold 33,064 Travere Therapeutics shares in Q1 2026, an estimated $988K.
Travere Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #2885 holding.
JP Morgan Chase first reported a position in Travere Therapeutics in Q4 2015 and has held it in 41 quarters since.
JP Morgan Chase's Travere Therapeutics position peaked at $35.2M in Q4 2021.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.